CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02281448
NCT02281448Phase 1Completed
CompareCT.gov

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Volunteers

Bial - Portela C S.A.·interventional·Posted Nov 3, 2014·Updated Dec 3, 2014

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 and Contraceptives, Oral, Combined for Epilepsy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Single centre, two-way crossover, randomised, open-label study in 20 healthy female volunteers.The volunteers received an oral single-dose of a combined contraceptive containing with an oral once daily dose of 1200 mg of BIA 2-093

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2014
Enrollment StartMar 1, 2005
Primary CompletionMay 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.7 years ago

Interventions

BIA 2-093drug

Contraceptives, Oral, Combineddrug